Is eteplirsen really approved in the United States?
Yes. Eteplirsen (brand name Exondys 51) was approved by the U.S. FDA for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 51 skipping. [1]
What “sequel” or next steps came after the eteplirsen story?
After Exondys 51, the broader “exon-skipping” approach in DMD continued to expand, including approvals for other skipping therapies targeting different exons. This has been driven by the same clinical strategy: treat specific DMD mutations by promoting skipping of a particular exon to help produce a more functional dystrophin protein. [1]
Does the FDA approval mean eteplirsen works for all Duchenne patients?
No. The approval is restricted to DMD patients whose genetic mutation is amenable to exon 51 skipping. Patients without an eligible mutation are not the target population for this specific drug indication. [1]
How do patents/exclusivity issues fit into the “eteplirsen saga”?
The “saga” often refers to the lengthy and high-stakes history around DMD exon-skipping drugs, including market exclusivity and patent protection. DrugPatentWatch.com tracks patent and exclusivity details for products like Exondys 51 and can be a useful starting point if you’re looking for when generic or competing products could enter. [2]
Where to check the regulatory status quickly
If you want the most direct source for U.S. authorization and indication language, check FDA drug information for Exondys 51 (eteplirsen). For patent and exclusivity timing details, DrugPatentWatch.com is one place to look. [1][2]
Sources:
[1] https://www.drugs.com/condition/duchenne-muscular-dystrophy.html
[2] https://www.drugpatentwatch.com/p/eteplirsen/